Healthcare provider profile · identity verified

Grace Marania, MD

Family Practice · MERCED, CA · NPI 1306115498

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	335	127
Rosuvastatin Calcium	Rosuvastatin Calcium	259	106
Losartan Potassium	Losartan Potassium	177	69
Lisinopril	Lisinopril	170	69
Amlodipine Besylate	Amlodipine Besylate	158	68
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	143	47
Ozempic	Semaglutide	108	23
Pantoprazole Sodium	Pantoprazole Sodium	96	42
Levothyroxine Sodium	Levothyroxine Sodium	94	41
Atenolol	Atenolol	91	31
Potassium Chloride	Potassium Chloride	86	43
Meloxicam	Meloxicam	84	44
Metformin Hcl Er	Metformin Hcl	80	37
Omeprazole	Omeprazole	77	37
Spiriva Respimat	Tiotropium Bromide	77	23
Metformin Hcl	Metformin Hcl	74	33
Simvastatin	Simvastatin	74	31
Triamcinolone Acetonide	Triamcinolone Acetonide	70	35
Gabapentin	Gabapentin	67	31
Jardiance	Empagliflozin	66	25
Sertraline Hcl	Sertraline Hcl	62	24
Albuterol Sulfate Hfa	Albuterol Sulfate	60	33
Tamsulosin Hcl	Tamsulosin Hcl	58	18
Montelukast Sodium	Montelukast Sodium	53	21
Trazodone Hcl	Trazodone Hcl	53	24
Furosemide	Furosemide	52	23
Hydrochlorothiazide	Hydrochlorothiazide	51	19
Tramadol Hcl	Tramadol Hcl	51	16
Wixela Inhub	Fluticasone Propion/Salmeterol	49	17
Breyna	Budesonide/Formoterol Fumarate	47	21
Metoprolol Tartrate	Metoprolol Tartrate	45	17
Bisoprolol Fumarate	Bisoprolol Fumarate	39	15
Ibuprofen	Ibuprofen	37	24
Glipizide	Glipizide	35	21
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	35	16
Prednisone	Prednisone	35	34
Alendronate Sodium	Alendronate Sodium	34	14
Humulin N	Insulin Nph Human Isophane	34	15
Benazepril Hcl	Benazepril Hcl	32	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	31	suppressed
Spironolactone	Spironolactone	31	15
Allopurinol	Allopurinol	30	14
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	29	12
Famotidine	Famotidine	28	suppressed
Carvedilol	Carvedilol	24	suppressed
Naproxen	Naproxen	24	suppressed
Colchicine	Colchicine	23	suppressed
Nabumetone	Nabumetone	22	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	22	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Eliquis	Apixaban	20	suppressed
Ezetimibe	Ezetimibe	20	suppressed
Ondansetron Odt	Ondansetron	20	11
Clindamycin Hcl	Clindamycin Hcl	19	16
Duloxetine Hcl	Duloxetine Hcl	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	12
Clopidogrel	Clopidogrel Bisulfate	18	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	18	suppressed
Terazosin Hcl	Terazosin Hcl	18	suppressed
Metoprolol Succinate	Metoprolol Succinate	17	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Liraglutide	Liraglutide	16	suppressed
Nystatin	Nystatin	16	12
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	15	15
Clonidine Hcl	Clonidine Hcl	15	suppressed
Estradiol	Estradiol	15	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Glimepiride	Glimepiride	15	suppressed
Pravastatin Sodium	Pravastatin Sodium	15	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	15	suppressed
Lactulose	Lactulose	14	11
Morphine Sulfate Er	Morphine Sulfate	14	suppressed
Humulin R	Insulin Regular, Human	13	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	11
Fluticasone Propionate	Fluticasone Propionate	11	suppressed
Temazepam	Temazepam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error